Hisashi Tagashira1, Yasuhisa Izushi2,3, Tomoki Ikuta4, Yasumasa Koike4, Yoshihisa Kitamura2, Hiroshi Yamamoto5. 1. Department of Pharmacy, National Hospital Organization Okayama Medical Centre, Okayama, Japan; tagashira.hisashi.je@mail.hosp.go.jp. 2. Department of pharmacotherapy, School of Pharmacy, Shujitsu University, Okayama, Japan. 3. Division of Molecular and Cellular Medicine, Department of Clinical Science, National Hospital Organization Okayama Medical Centre, Okayama, Japan. 4. Department of Pharmacy, National Hospital Organization Shikoku Cancer Centre, Ehime, Japan. 5. Department of Pharmacy, National Hospital Organization Okayama Medical Centre, Okayama, Japan.
Abstract
BACKGROUND/AIM: Extravasation associated with chemotherapy can induce localised injury, necrosis, and nerve damage, resulting in discontinued chemotherapy and impaired quality of life; however, risk factors for extravasation remain unclear. The present study aimed to identify chemotherapy regimen-associated factors related to extravasation. PATIENTS AND METHODS: Data on patient and chemotherapy protocol characteristics were extracted from our hospital's electronic database; the frequency of extravasation was compared among patients receiving different chemotherapy regimens. RESULTS: Twenty-two patients with extravasation undergoing chemotherapy during the study period were enrolled in the present study. Patients undergoing treatment with 5-fluorouracil and cisplatin were most likely to develop extravasation in the present study. All patients presenting with extravasation during treatment with 5-fluorouracil and cisplatin developed swelling and many (40%) developed erythema within the first two cycles of treatment. CONCLUSION: Treatment with 5-fluorouracil combined with cisplatin increases the incidence of extravasation. Ensuring suitable vascular access and increasing awareness regarding the symptoms and timing of extravasation among patients and medical staff can improve extravasation prevention and diagnosis. Copyright
BACKGROUND/AIM: Extravasation associated with chemotherapy can induce localised injury, necrosis, and nerve damage, resulting in discontinued chemotherapy and impaired quality of life; however, risk factors for extravasation remain unclear. The present study aimed to identify chemotherapy regimen-associated factors related to extravasation. PATIENTS AND METHODS: Data on patient and chemotherapy protocol characteristics were extracted from our hospital's electronic database; the frequency of extravasation was compared among patients receiving different chemotherapy regimens. RESULTS: Twenty-two patients with extravasation undergoing chemotherapy during the study period were enrolled in the present study. Patients undergoing treatment with 5-fluorouracil and cisplatin were most likely to develop extravasation in the present study. All patients presenting with extravasation during treatment with 5-fluorouracil and cisplatin developed swelling and many (40%) developed erythema within the first two cycles of treatment. CONCLUSION: Treatment with 5-fluorouracil combined with cisplatin increases the incidence of extravasation. Ensuring suitable vascular access and increasing awareness regarding the symptoms and timing of extravasation among patients and medical staff can improve extravasation prevention and diagnosis. Copyright
Authors: F Narducci; M Jean-Laurent; L Boulanger; S El Bédoui; Y Mallet; J L Houpeau; A Hamdani; N Penel; C Fournier Journal: Eur J Surg Oncol Date: 2011-08-09 Impact factor: 4.424
Authors: Jeannette Jackson-Rose; Judith Del Monte; Adrienne Groman; Linda S Dial; Leah Atwell; Judy Graham; Rosemary O'Neil Semler; Maryellen O'Sullivan; Lisa Truini-Pittman; Terri A Cunningham; Lisa Roman-Fischetti; Eileen Costantinou; Chris Rimkus; Adrienne J Banavage; Barbara Dietz; Carol J Colussi; Kimberly Catania; Michelle Wasko; Kevin A Schreffler; Colleen West; Mary Lou Siefert; Robert David Rice Journal: Clin J Oncol Nurs Date: 2017-08-01 Impact factor: 1.027
Authors: J A Pérez Fidalgo; L García Fabregat; A Cervantes; A Margulies; C Vidall; F Roila Journal: Eur J Oncol Nurs Date: 2012-12 Impact factor: 2.398